1-3 of 3
Esteban Cvitkovic, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL)

Eugenio Gaudio, Luciano Cascione, Maurilio Ponzoni, MD, Chiara Tarantelli, Elena Bernasconi, Maria Eugenia Riveiro, PhD, Esteban Cvitkovic, MD, Emanuele Zucca, Francesco Bertoni
Journal: Blood
Blood (2015) 126 (23): 5119.
https://doi.org/10.1182/blood.V126.23.5119.5119
Published: 2015
Journal Articles

Preclinical Evaluation of the BET-Bromodomain (BET-BRD) Inhibitor OTX015 in Leukemia Cell Lines Harboring the JAK2 V617F Mutation

Maria Eugenia Riveiro, PhD, Lucile Astorgues-Xerri, PhD, Charlotte Canet-jourdan, Mohamed Bekradda, MD, Esteban Cvitkovic, MD, Patrice Herait, MD, Eric Raymond, MD PhD
Journal: Blood
Blood (2014) 124 (21): 873.
https://doi.org/10.1182/blood.V124.21.873.873
Published: 2014
Journal Articles

The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL)

Michela Boi, Paola Bonetti, PhD, Maurilio Ponzoni, Maria Grazia Tibiletti, Anastasios Stathis, MD, Esteban Cvitkovic, MD, Giorgio Inghirami, Emanuele Zucca, MD, Francesco Bertoni, MD
Journal: Blood
Blood (2012) 120 (21): 4872.
https://doi.org/10.1182/blood.V120.21.4872.4872
Published: 2012